MedTrace Logo

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

NCT06458439 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-03-27

No results posted yet for this study

Summary

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

Conditions

  • Lymphoma, Non-Hodgkin
  • Relapsed Diffuse Large B Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • High-grade B-cell Lymphoma
  • Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Epcoritamab

* C1D1: fixed priming dose of 0.16 mg subcutaneous injection * C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection * C1D15 onward: fixed full dose of 48 mg subcutaneous injection

Sponsors & Collaborators

  • Genmab

    collaborator INDUSTRY

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Elise Chong, MD · Abramson Cancer Center at the University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-24
Primary Completion
2027-10-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06458439 on ClinicalTrials.gov